Identifying Novel Drug Targets in AD Using Brain Gene Expression
Nilufer Ertekin-Taner, MD, PhD
Mayo Clinic Jacksonville (Jacksonville, FL)
July 1, 2013 to June 30, 2016
Grant Reference ID:
Target Pathway Discovery in AD Using Transcriptomics
Genetic studies that survey the complete human genome for variants that associate with Alzheimer’s disease (AD) risk, could be key for identifying potential drug targets, though such studies cannot discover the precise mechanism of action of the genetic factors, which is a significant obstacle in the translation of their findings to therapies. Dr. Ertekin-Taner’s team has a novel approach in that they combine information from genetic studies of AD and from their large study on human brain gene expression, to discover how modifying the expression levels of specific genes in the brain can increase the risk of AD. In this proposal, Dr. Ertekin-Taner’s team plans to build upon their strong prior findings, and uncover the precise gene expression changes and their biological consequences that lead to increased risk of AD. The results from this proposal will enable innovative drug discovery approaches aimed at rectifying the misregulated brain gene expression that is likely to be involved with important disease-promoting mechanisms in AD.
Dr. Ertekin-Taner’s study aims to discover novel pathways in Alzheimer disease (AD) by identifying changes in the levels of genes found expressed in the brain that confer risk for this disease. The genes and proteins involved in these new pathways would then be future targets for disease-modifying drugs. This work is based on the strong rationale that the risk for many human diseases is influenced by genetic variants that modulate levels of genes in disease-relevant tissue (i.e., brain tissue for AD).
Dr. Ertekin-Taner’s group has already determined that the strongest genetic risk variants for AD that were detected in recent genomic screens, also associate with the brain expression levels of genes that are located close to the strong risk variants. Dr. Ertekin-Taner’s findings suggest that there are genetic variants that confer risk of AD by modifying the expression levels of genes in the brain. Many genes exist in different forms, called isoforms, which result in different protein products with diverse functions. Identifying the precise changes in brain levels of these gene isoforms will transform the understanding of risk mechanisms in AD, and will enable future novel therapeutic approaches.
Dr. Ertekin-Taner’s team will uncover the specific isoform level changes for the strongest Alzheimer risk genes, by using their unique collection of 202 brains that were generously donated by Alzheimer’s patients. The team will also identify the biological consequences of altering specific isoform levels for two risk genes by decreasing or increasing their levels in cellular models, and investigating functional outcomes such as cell survival. Dr. Ertekin-Taner expects to uncover gene isoform level changes that implicate novel pathways in AD that may guide future drug discovery efforts, and revolutionize therapeutic approaches.
About the Researcher
Dr. Nilüfer Ertekin-Taner is a neurogeneticist and board-certified behavioral neurologist at the Departments of Neuroscience and Neurology at Mayo Clinic Florida. After obtaining her medical degree at Hacettepe University Medical School, in Turkey, she received her Ph.D. from Mayo Graduate School, followed by residency in Neurology at Mayo Clinic Minnesota and fellowship in Behavioral Neurology at Mayo Clinic Florida. Since establishing her research program in 2008, her studies have focused on the genetics of Alzheimer’s disease. Her laboratory utilizes biological traits such as gene expression levels and cognitive endophenotypes to discover and characterize genetic factors underlying the complex genetics of Alzheimer disease. Dr. Ertekin-Taner is the PI of several projects aimed at characterization of brain gene expression in Alzheimer’s and other neurodegenerative diseases and has led one of the largest human brain transcriptome studies. In addition to her BrightFocus award, Dr. Ertekin-Taner’s laboratory is supported by the National Institutes of Health and CurePSP Society.
First published on: Monday, July 1, 2013
Last modified on: Friday, July 1, 2016